Arylalkylamine-, β-carboline-, quinolizine- and azecine-derived compounds and their in vitro interaction with the ionotropic 5-HT3 receptor: Search for new lead structures

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 9, 2010, Pages 544-552

  Enzensperger, Christoph ^a,c   Lehmann, Jochen ^a   Von Schroetter, Katrin ^b   Riyazi, Anja ^b   Verspohl, Eugen J ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNILEVER RESEARCH   (United Kingdom)

Author keywords

Azecine; Phenylalkylamine; Quinolizine; carboline

Indexed keywords

ARALKYLAMINE; BETA CARBOLINE DERIVATIVE; CARBON 14; DOPAMINE RECEPTOR BLOCKING AGENT; GUANIDINE; QUINOLIZINE DERIVATIVE; SEROTONIN 2A ANTAGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; TROPISETRON; VERATRIDINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; ILEUM; ILEUM CONTRACTION; IN VITRO STUDY; MOUSE; MUSCLE RELAXATION; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 77957660188     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296323     Document Type: Article

References (35)

1. Cash BD, Chey WD. Reviewarticle: The role of serotonergic agents in the treatment of patients with primary chronic constipation. Aliment Pharmacol Ther. 2005;22:1047-60.
2. Mössner R, Lesch KP. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav Immun. 1998;12:249-71. (Pubitemid 29224829)
3. Surgand JS, Rodrigo J, Rognan D. A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins. 2006;62:509-38.
4. Costall B, Domeney AM, Gerrard PA, Kelly ME, Naylor RJ. Zacopride: anxiolytic profile in rodent and primate models of anxiety. J Pharm Pharmacol. 1988:40:302-5.
5. Smith WT, Londborg PD, Blomgren SL, Tollefson GD, Sayler ME. Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety. J Clin Psychopharmacol. 1999;19:125-31.
6. Young R, Johnson DN. Anxiolytic-like activity of R(+)- and S(-)-zacopride in mice. Eur J Pharmacol. 1991;201:151-55.
7. Lodge NJ, Li YW. Ion channels as potential targets for the treatment of depression. Curr Opin Drug Discov Devel. 2008;11:633-41.
8. Buhot MC, Mallert G, Segul. Serotonin receptors and cognitive behaviour-an update. IDrugs. 1999;2:426-37.
9. Sirota P, Mosheva T, Shabtay H, Giladi N, Korczyn AD. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am J Psychiatry. 2000;157:287-9.
10. Zhang ZJ, Kang WH, Li Q, Wang XY, Yao SM, Ma AQ. Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: a double-blind, randomized, placebo-controlled study. Schizophr Res. 2006;88:102-10.
11. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell LC, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879-85.
12. McKinzie DL, McBride WJ, Murphy JM, Lumeng L, Li TK. Effects of MDL 72222, a serotonin3 antagonist, on operant responding for ethanol by alcohol-preferring P rats. Alcohol Clin Exp Res. 2000;24:1500-4.
13. Kankaanpaa A, Meririnne E, Seppala T. 5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacology (Berl). 2002;159:341-50. (Pubitemid 34143358)
14. Kos T, Popik P, Pietraszek M, Schafer D, Danysz W, Dravolina O, et al. Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by ketamine in rats and mice. Eur Neuropsychopharmacol. 2006;16:297-10.
15. Yoo JH, Nam YS, Lee SY, Jang CG. Dopamine neurotransmission is involved in the attenuating effects of 5-HT3 receptor antagonist MDL 72222 on acute methamphetamine-induced locomotor hyperactivity in mice. Synapse. 2008;62:8-13.
16. Fontana DJ, Daniels SE, Eglen RM, Wong EH. Stereoselective effects of (R)- and (S)-zacopride on cognitive performance in a spatial navigation task in rats. Neuropharmacology. 1996;35:321-327.
17. Fontana DJ, Daniels SE, Henderson C, Eglen RM, Wong EH. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. Psychopharmacology (Berl). 1995;120:409-17.
18. Bönisch H, Barann M, Graupner J, Göthert M. Characterization of 5-HT3 receptors of N1E-115 neuroblastoma cells by use of the influx of the organic cation [14C]-guanidinium. Br J Pharmacol. 1993;108:436-42.
19. Abdel-Aziz H, Nahrstedt A, Petereit F, Windeck T, Ploch M, Verspohl EJ. 5-HT3 receptor blocking activity of arylalkanes isolated from the rhizome of Zingiber officinale. Planta Med. 2005;71:609-16.
20. Glennon RA, Raghupathi R, Bartyzel P, Teitler M, Leonhardt S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J Med Chem. 1992;35:734-40.
21. Glennon RA, Gessner PK. Serotonin receptor binding affinities of tryptamine analogues. J Med Chem. 1979;22:428-32.
22. Ho BT, Li KC, Walker KE, Tansey LW, Kralik PM, McIsaac WM. Inhibitors of monoamine oxidase. VI. Effects of substitution on inhibitory activity of 6 (or 8)-substituted betacarbolines. J Pharm Sc. 1970;59:1445-8.
23. Schott Y, Decker M, Rommelspacher H, Lehmann J. 6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors. Bioorg Med Chem Lett. 2006;16:5840-3.
24. Fourneau JP, Delestrange Y. Dérives de la N- phényléthylènediamine. Bull Soc Chim France. 1947;14:827-38. French.
25. Schmutz J, Kunzle F. Piperazino-1′,2-1,2-Benzimidazole. Helv Chim Acta. 1956;39:1144-56.
26. Hoefgen B Decker M, Mohr P, Schramm AM, Rostom SA, El Subbagh H, et al. Dopamine/serotonin receptor ligands. 10: SAR studies on azecine-type dopamine receptor ligands by functional screening at human cloned D1, D2L, and D5 receptors with a microplate reader based calcium assay lead to a novel potent D1/D5 selective antagonist. J Med Chem. 2006;49:760-9.
27. Mohr P, Decker M, Enzensperger C, Lehmann J. Dopamine/serotonin receptor ligands. 12(1): SAR studies on hexahydro-dibenz[d,g]azecines lead to 4-chloro-7-methyl- 5,6,7,8,9,14-hexahydrodibenz[d,g]azecin-3-ol, the first picomolar D5-selective dopamine-receptor antagonist. J Med Chem. 2006;49:2110-6.
28. Enzensperger C, Gornemann T, Pertz HH, Lehmann J. Dopamine/serotonin receptor ligands. Part 17: A cross-target SAR approach: affinities of azecine-styled ligands for 5-HT(2A) versus D(1) and D(2) receptors. Bioorg Med Chem Lett. 2008;18(13):3809-13.
29. Enzensperger C, Kilian S, Ackermann M, Koch A, Kelch K, Lehmann J. Dopamine/serotonin receptor ligands. Part 15: Oxygenation of the benz-indolo-azecine LE 300 leads to novel subnanomolar dopamine D1/D5 antagonists. Bioorg Med Chem Lett. 2007;17:1399-402.
30. Wernicke C, Schott Y, Enzensperger C, Schulze G, Lehmann J. Cytotoxicity of beta-carbolines in dopamine transporter expressing cells: structure-activity relationships. Biochem Pharmacol. 2007;74:1065-77.
31. Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol. 2006;530:136-43.
32. Lopez-Rodriguez ML Morcillo MJ, Benhamu B, Rosado ML. Comparative receptor mapping of serotoninergic 5-HT3 and 5-HT4 binding sites. J Comput Aided Mol Des. 1997;11:589-99.
33. Heinzelmann RV, Anthony WC, Lyttle DA, Szmuszkovicz J. The synthesis of α-methyltryptophans and α-alkyltryptamines. J Org Chem. 1960;25:1548-58.
34. Enzensperger C, Lehmann J. Dopamine/serotonin receptor ligands. 13: Homologization of a benzindoloazecine-type dopamine receptor antagonist modulates the affinities for dopamine D(1)-D(5) receptors. J Med Chem. 2006;49:6408-11.
35. Enzensperger C, Müller FK, Schmalwasser B, Wiecha P, Traber H, Lehmann J. Dopamine/serotonin receptor ligands. 16.(1) Expanding dibenz[d,g]azecines to 11- and 12-membered homologues. Interaction with dopamine D(1)-D(5) receptors. J Med Chem. 2007;50:4528-33.